Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: sammaster who wrote (1632)	12/18/2005 1:25:29 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

That is most probably one of the factors influencing the share price negatively. This question was asked at the recent London presentation. Moulder claimed, that he didn't see much of a disadvantage (what else could he say?). His reasoning. Hospitals. At the beginning of the year they were on the formularies of 20 % of the hospitals. Over the year they have added another 40 %, despite the fact that these hospitals know that Zofran will go generic. Evidently, he says, these hospitals prefer Aloxi due to the more favourable profile. This is, he says, "evidence" that these hospitals will be using Aloxi despite the fact that Zofran is going generic. As a matter of fact, he expects the company to sell more to hospitals next year when compared with this year. Clinics. He claims that there will still be a reimbursement advantage in favour of Aloxi, when Zofran has gone genric. That is, the people running the clinics are not interested in the actual cost of the drug, but only in which drug will bring them the best net. Which he claims Aloxi will continue to do with the exception of a period of 2 to 3 quarters during the change-over. The webcast is still available at investorcalendar.com The question and answer comes about 36 minutes into the presentation. Erik